# Anvisa approval of GLP-1 medications in Brazil

> Developing situation record from CLSTR: https://clstr.news/situations/anvisa-approval-of-glp-1-medications-in-brazil
> Updated: 2026-11-01T15:56:00.000Z. Sources: 38. Developments: 2.

Brazil’s National Health Surveillance Agency (Anvisa) has approved the registration of five new GLP-1 receptor agonist medication pens for treating diabetes and obesity. These new products include Aribet, Lyrza, and Wylovol, which are based on liraglutide, as well as Embeltah and Sevema, which are based on semaglutide.

The approved medications are registered by Farma Vision Importação e Exportação de Medicamentos, Dr. Reddy’s Farmacêutica do Brasil, and Aché Laboratórios Farmacêuticos. Manufacturing for these products is linked to Indian laboratories Biocon and OneSource Specialty.

With these latest approvals, Anvisa has authorized a total of 20 GLP-1 applicator pens in 2026. This regulatory activity follows a decision by Anvisa in August 2025 to prioritize the analysis of semaglutide and liraglutide medications, a move prompted by the Ministry of Health to support the Unified Health System (SUS) and stabilize the national market supply.

## Claims

- Anvisa approved the registration of five new injectable medications for type 2 diabetes and obesity. (reported by 2 sources)
- The new medications contain semaglutide or liraglutide. (reported by 2 sources)
- The medications are produced by Biocon and OneSource Specialty. (reported by 2 sources)
- Aribet, Embeltah, and Sevema are indicated for diabetes treatment. (reported by 2 sources)
- Lyrza and Wylovol are indicated for obesity treatment. (reported by 2 sources)
- Anvisa has approved a total of 20 GLP-1 applicator pens to date. (reported by 2 sources)

## Timeline

### 2026-11-01: Anvisa approves five new injectable pens for diabetes and obesity

Anvisa has approved five new GLP-1 injectable pens for diabetes and obesity treatment in Brazil, manufactured by Indian labs Biocon and OneSource Specialty.

28 sources. https://clstr.news/cluster/anvisa-approves-five-new-injectable-pens-for-diabetes-and-obesity

### 2026-10-29: Anvisa approves five new diabetes and obesity medication pens in Brazil

Brazil's Anvisa approved five new GLP-1 medication pens for diabetes and obesity, bringing the 2026 total to 20 approvals.

10 sources. https://clstr.news/cluster/anvisa-approves-five-new-glp-1-medications-in-brazil

---
Cite as: Anvisa approval of GLP-1 medications in Brazil. CLSTR, https://clstr.news/situations/anvisa-approval-of-glp-1-medications-in-brazil
